Biotech Values

[mcbio]

Re: ANDS (vs. ACHN)

Alright, so ANDS is essentially down to one HCV compound and that sole remaining compound has already shown that it has significant toxicity concerns. ACHN, by contrast, has its next generation PI for HCV that is about to enter Phase I PoC trials. I realize ACHN hasn't yet demonstrated that the compound works but the point is that there's still that potential upside. I don't think one can realistically conclude that ANA598 has any upside given the significant safety concerns. Despite that, ANDS still trades at almost twice the market cap of ACHN. I find that a bit absurd (and inefficient).